keyword
https://read.qxmd.com/read/38317672/direct-oral-anticoagulants-compared-to-warfarin-in-long-term-management-of-cerebral-venous-thrombosis-a-comprehensive-meta-analysis
#21
JOURNAL ARTICLE
Redoy Ranjan, Gie Ken-Dror, Pankaj Sharma
OBJECTIVES: We compared the safety and efficacy of direct oral anticoagulants (DOACs) with those of warfarin in the long-term (≥6 months) treatment of cerebral venous thrombosis (CVT). METHODS: We searched electronic databases up to November 2023 to compare the use of DOACs and warfarin in CVT management. Modified Rankin scores (mRS), new intracranial hemorrhage, all-cause mortality, recurrence and nonrecanalisation events were used to assess outcome. RevMan v5...
February 2024: Health Science Reports
https://read.qxmd.com/read/38277234/payer-approval-and-rejection-of-oral-anticoagulant-prescriptions-and-prescription-abandonment-patterns-among-patients-with-venous-thromboembolism
#22
JOURNAL ARTICLE
Dionne M Hines, Riddhi Doshi, Vamshi Ruthwik Anupindi, Feng Dai, Cristina Russ, Robert Stellhorn, Dong Cheng, Serina Deeba, Yi Wang, Mitchell DeKoven
BACKGROUND: Venous thromboembolism (VTE) is a major public health condition that renders patients at risk of recurrent events, which significantly increases their morbidity, mortality, and health care costs. Apart from warfarin, direct oral anticoagulants, such as apixaban, dabigatran, or rivaroxaban, are approved for VTE treatment. Cardiovascular drugs are largely impacted by formulary restrictions; however, the impact on oral anticoagulants (including warfarin and direct oral anticoagulants) in VTE has not been well studied...
January 26, 2024: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/38266751/comparison-of-different-direct-oral-anticoagulant-regimens-in-atrial-fibrillation-patients-with-high-bleeding-risk
#23
JOURNAL ARTICLE
Wei-Siang Ciou, Chi-Chuan Wang, Fang-Ju Lin, Tze-Fan Chao, Shin-Yi Lin
BACKGROUND: The optimal dose of Direct oral anticoagulants (DOACs) to prevent ischemic stroke (IS) and systemic thromboembolism (STE) in atrial fibrillation (AF) patients with a predisposing bleeding risk remains unclear. OBJECTIVE: To compare the effectiveness and safety of different DOAC dosage regimens in AF patients with a high bleeding risk but a low thrombosis risk. METHODS: This retrospective, observational study was conducted with the National Health Insurance claims database in Taiwan to include AF patients aged 20 to <75 years, under DOAC therapy, had a CHA2 DS2 -VASc score of 1 for male and 2 for female and a HAS-BLED score ≥ 3...
January 22, 2024: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://read.qxmd.com/read/38264795/non-vitamin-k-antagonist-oral-anticoagulants-noacs-after-acute-myocardial-infarction-a-network-meta-analysis
#24
REVIEW
Samer Al Said, Klaus Kaier, Wael Sumaya, Dima Alsaid, Daniel Duerschmied, Robert F Storey, C Michael Gibson, Dirk Westermann, Samer Alabed
BACKGROUND: Balancing the risk of bleeding and thrombosis after acute myocardial infarction (AMI) is challenging, and the optimal antithrombotic therapy remains uncertain. The potential of non-vitamin K antagonist oral anticoagulants (NOACs) to prevent ischaemic cardiovascular events is promising, but the evidence remains limited. OBJECTIVES: To evaluate the efficacy and safety of non-vitamin-K-antagonist oral anticoagulants (NOACs) in addition to background antiplatelet therapy, compared with placebo, antiplatelet therapy, or both, after acute myocardial infarction (AMI) in people without an indication for anticoagulation (i...
January 24, 2024: Cochrane Database of Systematic Reviews
https://read.qxmd.com/read/38213182/retrospective-study-of-clinical-settings-indications-and-consequences-of-measurement-of-direct-oral-anticoagulant-plasma-levels-in-northern-tasmania-australia
#25
JOURNAL ARTICLE
Ming S Lim, Muhajir Mohamed
BACKGROUND: Routine monitoring of direct oral anticoagulant (DOAC) levels is not recommended but may be useful in certain clinical situations. There is a knowledge gap regarding the clinical use of DOAC levels in Australian hospitals. AIMS: To evaluate the clinical settings, indications and changes to anticoagulant management associated with DOAC levels in a tertiary hospital in Northern Tasmania, Australia. METHODS: Patients with one or more DOAC levels (dabigatran, rivaroxaban or apixaban) requested between January 2017 and December 2022 were identified...
January 11, 2024: Internal Medicine Journal
https://read.qxmd.com/read/38197017/direct-acting-oral-anticoagulants-in-patients-at-extremes-of-body-weight-a-review-of-pharmacological-considerations-and-clinical-implications
#26
REVIEW
Rosa Talerico, Roberto Pola, Frederikus Albertus Klok, Menno Volkert Huisman
Patients at extremes of body weight are underrepresented in randomized controlled trials of direct-acting oral anticoagulants (DOACs). Therefore, their optimal anticoagulant treatment remains a topic of debate. The aim of this narrative review is to summarize the evidence on the pharmacokinetic and pharmacodynamic profile of DOACs for treating patients at extremes of body weight in venous thromboembolism (VTE) and in the prevention of cardioembolic stroke in nonvalvular atrial fibrillation (NVAF). A literature search was conducted in the main bibliographic databases, and the most relevant reviews and original articles on the topic were selected...
January 2024: TH Open: Companion Journal to Thrombosis and Haemostasis
https://read.qxmd.com/read/38194191/antithrombotic-prophylaxis-following-total-hip-arthroplasty-a-level-i-bayesian-network-meta-analysis
#27
Filippo Migliorini, Nicola Maffulli, Erlis Velaj, Andreas Bell, Daniel Kämmer, Frank Hildebrand, Ulf Krister Hofmann, Jörg Eschweiler
BACKGROUND: Several clinical investigations have compared different pharmacologic agents for the prophylaxis of venous thromboembolism (VTE). However, no consensus has been reached. The present investigation compared enoxaparin, fondaparinux, aspirin and non-vitamin K antagonist oral anticoagulants (NOACs) commonly used as prophylaxis following total hip arthroplasty (THA). A Bayesian network meta-analysis was performed, setting as outcomes of interest the rate of deep venous thrombosis (DVT), pulmonary embolism (PE) and major and minor haemorrhages...
January 9, 2024: Journal of Orthopaedics and Traumatology: Official Journal of the Italian Society of Orthopaedics and Traumatology
https://read.qxmd.com/read/38190093/comparison-of-vitamin-k-and-non-vitamin-k-oral-anticoagulants-and-the-bleeding-frequency-in-the-emergency-department
#28
JOURNAL ARTICLE
Tomo Svaguša, Stjepan Šimić, Filip Grabant, Tatjana Kereš, Ognjen Čančarević, Frane Paić, Danijela Grizelj, Aleksandar Blivajs, Tomislav Bulum, Ingrid Prkačin
INTRODUCTION: Safety studies of anticoagulant therapy have so far been conducted on many subjects in controlled conditions (i.e., clinically monitored) and demonstrated the noninferiority of new ones over old anticoagulant drugs. Data on the propositions for the presence of symptoms and signs of bleeding among various anticoagulants in the emergency department indicate that these data do not match the data published so far. AIM: The aim of the study was to investigate the differences in the frequency of bleeding and bleeding-related symptoms as a reason for emergency department attendance in patients on anticoagulant therapy...
January 8, 2024: High Blood Pressure & Cardiovascular Prevention: the Official Journal of the Italian Society of Hypertension
https://read.qxmd.com/read/38180321/treatment-of-atrial-fibrillation
#29
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
January 8, 2024: Medical Letter on Drugs and Therapeutics
https://read.qxmd.com/read/38137783/pharmacogenomic-considerations-for-anticoagulant-prescription-in-patients-with-hereditary-haemorrhagic-telangiectasia
#30
JOURNAL ARTICLE
Sarah C McCarley, Daniel A Murphy, Jack Thompson, Claire L Shovlin
Hereditary haemorrhagic telangiectasia (HHT) is a vascular dysplasia that commonly results in bleeding but with frequent indications for therapeutic anticoagulation. Our aims were to advance the understanding of drug-specific intolerance and evaluate if there was an indication for pharmacogenomic testing. Genes encoding proteins involved in the absorption, distribution, metabolism, and excretion of warfarin, heparin, and direct oral anticoagulants (DOACs) apixaban, rivaroxaban, edoxaban, and dabigatran were identified and examined...
December 15, 2023: Journal of Clinical Medicine
https://read.qxmd.com/read/38112731/head-to-head-ex-vivo-comparison-of-clinically-used-direct-anticoagulant-drugs
#31
JOURNAL ARTICLE
Jaka Fadraersada, Raúl Alva-Gallegos, Pavel Skořepa, František Musil, Lenka Javorská, Kateřina Matoušová, Lenka Kujovská Krčmová, Markéta Paclíková, Alejandro Carazo, Vladimír Blaha, Přemysl Mladěnka
An imbalance in coagulation is associated with cardiovascular events. For prevention and treatment, anticoagulants, currently mainly xabans and gatrans, are used. The purpose of the present study was to provide a head-to-head comparison since there are no studies directly evaluating these novel anticoagulants. An additional aim was to find whether selected anthropological and biochemical factors can affect their anticoagulant properties as they are used in fixed doses. In this cross-sectional study, blood from 50 generally healthy donors was collected, and coagulation responses to dabigatran, argatroban, rivaroxaban, and apixaban, at a concentration of 1 μM, were analyzed...
December 19, 2023: Naunyn-Schmiedeberg's Archives of Pharmacology
https://read.qxmd.com/read/38101950/development-of-a-rapid-qualitative-screen-for-anticoagulant-presence
#32
JOURNAL ARTICLE
Selena Wong, Jenna Slingerland, Jane A Dickerson, Jennifer Pak, Gavin D Roach, Nabiha H Saifee
BACKGROUND: Direct oral anticoagulants (DOACs) and fondaparinux with stable pharmacokinetics are commonly used anticoagulants for outpatient care. Due to the lack of monitoring requirements, drug-specific assays are not available in most hospital laboratories, but drug levels are needed in some urgent/emergency situations. This study describes the development of a qualitative screen for the presence of DOAC or fondaparinux using coagulation tests found in most laboratories. METHODS: The DOAC screen is composed of a heparin anti-Xa activity assay and thrombin time (TT) assay...
December 15, 2023: Journal of Applied Laboratory Medicine
https://read.qxmd.com/read/38095004/dementia-risk-of-direct-oral-anticoagulants-versus-warfarin-for-atrial%C3%A2-fibrillation-systematic-review-and-meta-analysis
#33
JOURNAL ARTICLE
Khi Yung Fong, Yiong Huak Chan, Yue Wang, Colin Yeo, Barbara Helen Rosario, Gregory Y H Lip, Vern Hsen Tan
BACKGROUND: Direct-acting oral anticoagulants (DOACs) have demonstrated superior efficacy in preventing stroke and death compared with warfarin in patients with atrial fibrillation (AF), but their influence on dementia risk remains unclear. OBJECTIVES: The purpose of this study was to evaluate the relative risks of dementia in DOAC vs warfarin in patients with AF. METHODS: An electronic literature search was conducted to retrieve studies reporting comparisons of dementia incidence between patients treated with DOACs and warfarin for AF...
October 2023: JACC Asia
https://read.qxmd.com/read/38076271/real-world-national-trends-and-influencing-factors-preference-of-non-vitamin-k-antagonist-oral-anticoagulants-in-china
#34
JOURNAL ARTICLE
Shaojing Zhu, Mengjie Li, Lujun Wang, Lu Hou, Dandan Li, Jiuhong Liu, Yanxia Lu
BACKGROUNDS: Non-vitamin K antagonist oral anticoagulants (NOACs) have been recommended as the first choice over warfarin for non-valvular atrial fibrillation (AF). However, there is limited data about their usage in mainland China. METHODS: Prescriptions of patients diagnosed with AF and containing OACs were extracted from Hospital Prescription Cooperation Project from January 2016 to March 2021. The primary outcome was the changing percentage of different OACs...
2023: Frontiers in Medicine
https://read.qxmd.com/read/38070219/real-life-results-of-direct-acting-oral-anticoagulants-recommended-dose-in-obese-vs-normal-weight-patients-with-venous-thromboembolism
#35
JOURNAL ARTICLE
José Antonio Rueda-Camino, Raquel Barba, Sonia Otálora, Alessandra Bura-Riviere, Adriana Visonà, Isabelle Mahé, Alicia Alda-Lozano, Joaquín Alfonso Megido, Nazaret Pacheco-Gómez, Rachel P Rosovsky, Manuel Monreal
BACKGROUND: There is scarce evidence on the effectiveness and safety of recommended-dose direct acting oral anticoagulants (DOACs) in obese patients with venous thromboembolism (VTE). MATERIAL AND METHODS: We used the data in the RIETE registry to compare the rates of VTE recurrences and major bleeding during long-term therapy with DOACs at recommended doses in patients with body mass index ≥30 kg/m2 (obese) vs. those with BMI 18.5-24.9 kg/m2 (normal weight)...
December 5, 2023: Thrombosis Research
https://read.qxmd.com/read/38062723/risk-factors-for-anticoagulant-associated-gastrointestinal-hemorrhage-a-systematic-review-and-meta-analysis
#36
JOURNAL ARTICLE
Fuxin Ma, Shuyi Wu, Shiqi Li, Zhiwei Zeng, Jinhua Zhang
BACKGROUND/AIMS: There may be many predictors of anticoagulation-related gastrointestinal bleeding (GIB), but until now, systematic reviews and assessments of the certainty of the evidence have not been published. We conducted a systematic review to identify all risk factors for anticoagulant-associated GIB to inform risk prediction in the management of anticoagulation- related GIB. METHODS: A systematic review and meta-analysis were conducted to search PubMed, EMBASE, Web of Science, and Cochrane Library databases (from inception through January 21, 2022) using the following search terms: anticoagulants, heparin, warfarin, dabigatran, rivaroxaban, apixaban, DOACs, gastrointestinal hemorrhage, risk factors...
December 8, 2023: Korean Journal of Internal Medicine
https://read.qxmd.com/read/38043043/2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the-american-college-of-cardiology-american-heart-association-joint%C3%A2-committee%C3%A2-on%C3%A2-clinical-practice-guidelines
#37
José A Joglar, Mina K Chung, Anastasia L Armbruster, Emelia J Benjamin, Janice Y Chyou, Edmond M Cronin, Anita Deswal, Lee L Eckhardt, Zachary D Goldberger, Rakesh Gopinathannair, Bulent Gorenek, Paul L Hess, Mark Hlatky, Gail Hogan, Chinwe Ibeh, Julia H Indik, Kazuhiko Kido, Fred Kusumoto, Mark S Link, Kathleen T Linta, Gregory M Marcus, Patrick M McCarthy, Nimesh Patel, Kristen K Patton, Marco V Perez, Jonathan P Piccini, Andrea M Russo, Prashanthan Sanders, Megan M Streur, Kevin L Thomas, Sabrina Times, James E Tisdale, Anne Marie Valente, David R Van Wagoner
AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline...
January 2, 2024: Journal of the American College of Cardiology
https://read.qxmd.com/read/38038171/comparing-efficacy-and-safety-between-patients-with-atrial-fibrillation-taking-direct-oral-anticoagulants-or-warfarin-after-direct-oral-anticoagulant-failure
#38
JOURNAL ARTICLE
Meng-Tsang Hsieh, Chi-Hung Liu, Sheng-Hsiang Lin, Po-Yu Lin, Yu-Ming Chang, Chun-Min Wang, Chih-Hung Chen, Pi-Shan Sung
BACKGROUND: An increased risk of recurrent stroke is noted in patients with atrial fibrillation despite direct oral anticoagulant (DOAC) use. We investigated the efficacy and safety of treatment with each of 4 different DOACs or warfarin after DOAC failure. METHODS AND RESULTS: We retrospectively analyzed patients with atrial fibrillation with ischemic stroke despite DOAC treatment between January 2002 and December 2016. The different outcomes of patients with DOAC failure were compared, including recurrent ischemic stroke, major cardiovascular events, intracranial hemorrhage and subarachnoid hemorrhage, mortality, and net composite outcomes according to switching to different DOACs or vitamin K antagonist after index ischemic stroke...
December 1, 2023: Journal of the American Heart Association
https://read.qxmd.com/read/38035566/anticoagulation-in-patients-with-chronic-kidney-disease
#39
REVIEW
Elias John Elenjickal, Christoforos K Travlos, Pedro Marques, Thomas A Mavrakanas
BACKGROUND: Both atrial fibrillation and venous thromboembolic disease (VTE) are highly prevalent among patients with chronic kidney disease (CKD). Until recently, warfarin was the most commonly prescribed oral anticoagulant. Direct oral anticoagulants (DOACs) have important advantages and have been shown to be non-inferior to warfarin with respect to stroke prevention or recurrent VTE in the general population, with lower bleeding rates. This review article will provide available evidence on use of DOACs in patients with CKD...
November 30, 2023: American Journal of Nephrology
https://read.qxmd.com/read/38033089/2023-acc-aha-accp-hrs-guideline-for-the-diagnosis-and-management-of-atrial-fibrillation-a-report-of-the-american-college-of-cardiology-american-heart-association-joint-committee-on-clinical-practice-guidelines
#40
REVIEW
José A Joglar, Mina K Chung, Anastasia L Armbruster, Emelia J Benjamin, Janice Y Chyou, Edmond M Cronin, Anita Deswal, Lee L Eckhardt, Zachary D Goldberger, Rakesh Gopinathannair, Bulent Gorenek, Paul L Hess, Mark Hlatky, Gail Hogan, Chinwe Ibeh, Julia H Indik, Kazuhiko Kido, Fred Kusumoto, Mark S Link, Kathleen T Linta, Gregory M Marcus, Patrick M McCarthy, Nimesh Patel, Kristen K Patton, Marco V Perez, Jonathan P Piccini, Andrea M Russo, Prashanthan Sanders, Megan M Streur, Kevin L Thomas, Sabrina Times, James E Tisdale, Anne Marie Valente, David R Van Wagoner
AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted from May 12, 2022, to November 3, 2022, encompassing studies, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline...
November 30, 2023: Circulation
keyword
keyword
105049
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.